肿瘤相关巨噬细胞(TAMs)与多种肿瘤的发生和转移密切相关。TAMs的浸润用于预测癌症的预后,包括结直肠癌(CRC)。然而,在CRC中,瘤内M1和M2TAM表型与侵袭性前沿(IF)的密度和预后意义尚不清楚.在这项研究中,选择CD68作为TAM的一般标志物,CD11c,NOS2和CXCL10作为M1表型的标志物,CD163、CD206、CD115作为M2表型的标志物。首先,免疫组织化学染色和双标记免疫荧光染色显示M1分子标志物(NOS2,CXCL10,CD11c)在IF和肿瘤内均低表达,M2分子标志物(CD163、CD206、CD115)主要在IF高表达。此外,我们还证明了三个M1分子标记,包括NOS2,CXCL10和CD11c彼此相关。同时,3种M2分子标志物,包括CD163,CD206和CD115也相互关联.三种M1分子标志物(NOS2/CXCL10/CD11c)低表达的患者总生存率(OS)较低,而三个M2分子标志物(CD163/CD206/CD115)高表达的患者表现出较低的OS率。我们还观察到,三标记物组合(NOS2/CXCL10/CD11c或CD163/CD206/CD115)的预后价值优于单个标记物。一起,我们的研究结果揭示了TAMs标记物(NOS2/CXCL10/CD11c或CD163/CD206/CD115)的组合可以更好地评估CRC患者的预后,可作为一种更全面的预测CRC患者预后的方法。
Tumor-associated macrophages (TAMs) are closely related to tumorigenesis and metastasis of multiple cancer types. The infiltration of TAMs is used for predicting the prognosis of cancers, including colorectal cancer (CRC). However, the density and prognostic significance of M1 and M2 TAM phenotypes in the intratumor versus the invasive front (IF) are largely unknown in CRC. In this study, CD68 was selected as a general marker of TAMs, CD11c, NOS2 and CXCL10 as markers for M1 phenotype and CD163, CD206, CD115 as markers for M2 phenotype. Firstly, immunohistochemistry staining and double-labeling immunofluorescence staining showed that M1 molecular markers (NOS2, CXCL10, CD11c) were lowly expressed at both IF and intratumor, while M2 molecular markers (CD163, CD206, CD115) were highly expressed mainly at IF. Moreover, we also demonstrated that three M1 molecular markers including NOS2, CXCL10 and CD11c were correlated to each other. Meanwhile, three M2 molecular markers including CD163, CD206, and CD115 were also correlated to each other. Patients with low expression of three M1 molecular markers (NOS2/CXCL10/CD11c) exhibited low overall survival (OS) rate, whereas patients with high expression of three M2 molecular markers (CD163/CD206/CD115) exhibited low OS rate. We also observed that the prognostic value of treble markers combination (NOS2/CXCL10/CD11c or CD163/CD206/CD115) was superior to that of single marker. Together, our results reveal the combination of treble TAMs markers (NOS2/CXCL10/CD11c or CD163/CD206/CD115) could better evaluate the prognosis of CRC patients, which might be used as a more comprehensive method for predicting the prognosis of CRC patients.